Nel ASA’s EU Windfall and New Platform Put a Floor Under a Beaten-Down Stock

Nel ASA wins €135M EU grant to quadruple production capacity and launches cheaper alkaline electrolyzers, targeting 40-60% cost cuts to boost green hydrogen economics.

The Norwegian electrolyser maker is betting that a €135 million EU grant and a radically cheaper new product can rewrite the narrative around green hydrogen economics — even as its share price struggles to hold recent gains.

Nel ASA has secured the largest external funding commitment in its history, with the EU Innovation Fund pledging up to €135 million to cover as much as 60 percent of the industrialisation costs at its Herøya facility. The non-dilutive capital injection allows the company to pursue a fourfold expansion of annual production capacity — from 1 GW to 4 GW — without immediately tapping its own balance sheet. A first tranche of €11 million is expected to land in the second quarter of 2026.

The timing is no coincidence. On May 7, Nel commercially launched a new generation of pressurised alkaline electrolysis systems, the culmination of eight years of development. The platform operates at 30 bar and delivers hydrogen with 99.99 percent purity. But the headline number is the cost target: less than $1,450 per kilowatt for a 25-MW turnkey installation. That would represent a reduction of 40 to 60 percent against current market averages, which hover around $3,000 per kilowatt.

“Our technology is designed to enable business models that were previously not viable,” CEO Håkon Volldal said. The company is leaning heavily on standardisation and factory-built modular design to drive down complexity and installation costs. CTO Marius Løken noted the platform was engineered for “standardisation and industrial scale,” while CCO Todd Cartwright pointed to growing demand from industrial, infrastructure and even defence-related projects where ease of financing is becoming a dealbreaker.

The scale effects are expected to show up directly in capital expenditure. Internal projections point to a 40 to 60 percent drop in CAPEX for customers, a threshold that industry observers consider critical for making electrolysers economically attractive outside subsidised pilot projects.

Nel’s expansion plans at Herøya received a final investment decision in December 2025, and the EU grant now provides a clear funding path. The broader European policy environment is also shifting in the company’s favour. On May 6, the public consultation phase opened for the BarMar pipeline, which will connect Barcelona with Fos-sur-Mer as part of the H2med corridor. Designed to carry up to 2 million tonnes of renewable hydrogen annually by 2030 — roughly 10 percent of projected European demand — the pipeline underscores the continent’s commitment to building out hydrogen infrastructure. The European Commission has already awarded over €1 billion to nine hydrogen projects through its Hydrogen Bank.

Yet the market has so far greeted the twin catalysts with caution. Nel’s shares closed at €0.26 on Thursday, down nearly 8 percent on the day, and sit roughly 17 percent below the 52-week high touched in early May. The stock has still gained about 35 percent year to date, but the short-term momentum has stalled. The relative strength index sits at roughly 36, a level that typically signals oversold conditions.

Nel ended the first quarter with NOK 1.4 billion in liquidity, which management considers sufficient to fund operations through the end of 2026. The company is scheduled to report half-year results on July 15, and investors will be watching for signs that the new platform is converting interest into binding orders. That will be the real test of whether the technology leap can translate into commercial traction — and whether the stock’s recent retreat is a buying opportunity or a warning.